Yesterday, according to report, Epicutis, the science-driven luxury professional skincare brand, has secured $10 million in series B funding to propel its expansion into new frontiers. The funding, led by a longstanding board member and original supporter, follows a successful $3 million series A round just last October. With this influx, Epicutis plans to intensify its global distribution, accelerate product innovation, bolster marketing efforts, and enhance infrastructure.
Industry insiders anticipate significant growth, projecting revenues to reach $35 million this year and soar to $75 million next year, driven by a robust 200% annual sales acceleration and a commendable 65% reorder rate. Founded in 2020 as an offshoot of Signum Biosciences, Epicutis combines rigorous scientific research with skincare expertise, a legacy rooted in Jeffry Stock’s pioneering work in molecular biology.
Maxwell Stock, alongside Masanori Tamura and Lisa Johnson, has strategically positioned Epicutis at the nexus of clinical skincare, aesthetics, and simplified beauty trends. Their flagship products, including the acclaimed Lipid Serum and Hyvia Crème, epitomize the brand’s commitment to efficacy and purity, leveraging patented technologies like TSC and DSD.
Looking ahead, Epicutis plans to introduce new offerings, expand its presence in spas and med-spas across 16 countries, and explore emerging skincare markets in the APAC region, notably Australia. With a steadfast focus on professional channels and strategic partnerships, Epicutis aims to redefine skincare standards globally, guided by a mission to enhance skin health through innovation and scientific rigor.
